Search MRNA
Moderna, Inc.
Nasdaq · CIK 1682852
Last close190.01
Daily change+1.07 (0.57%)
10 Years gain+921.56%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MRNA · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
23.0Momentum
0.0Acceleration
0.0Confidence
84.0Annual Revenue10
Quarterly Revenue37
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality3.0 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
No positive signals calculated.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 46.9332 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 41.5191 percentage points.
Key Metrics
Revenue Growth TTM-28.85%OK
Revenue CAGR 3Y-53.44%OK
Gross Margin18.79%OK
Operating Margin-199.17%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-84.45%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.11%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.94B | $1.08B | -$3.07B | -$1.87B | -$2.07B | 55.35% | -158.13% | -106.22% | -66.38% | 389M |
| 2025 FY Dec 31, 2024 | $3.24B | $1.77B | -$3.95B | -$3.00B | -$4.06B | 54.76% | -121.91% | -125.31% | -68.3% | 384M |
| 2025 FY Dec 31, 2023 | $6.85B | $2.16B | -$4.24B | -$3.12B | -$3.83B | 31.47% | -61.9% | -55.86% | -46.28% | 382M |
| 2024 FY Dec 31, 2022 | $19.26B | $13.85B | $9.42B | $4.98B | $4.58B | 71.88% | 48.9% | 23.78% | 130.18% | 416M |
| 2023 FY Dec 31, 2021 | $18.47B | $15.85B | $13.30B | $13.62B | $13.34B | 85.83% | 71.98% | 72.2% | 1,781.49% | 431M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.69B | sum latest 4 fiscal quarters Revenue | OK | 0001682852-26-000150, 0001682852-25-000075 |
| Revenue Growth TTM | -28.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001682852-26-000150, 0001682852-25-000075 |
| Revenue CAGR 3Y | -53.44% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001682852-26-000033 |
| Revenue CAGR 5Y | 19.34% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001682852-26-000033 |
| Gross Profit CAGR 3Y | -57.33% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001682852-26-000033 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001682852-26-000150, 0001682852-25-000075 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 18.79% | Gross Profit / Revenue | OK | 0001682852-26-000150, 0001682852-25-000075 |
| Operating Margin | -199.17% | Operating Income / Revenue | OK | 0001682852-26-000150, 0001682852-25-000075 |
| ROIC | -84.45% | NOPAT / Average Invested Capital | OK | 0001682852-26-000150, 0001682852-25-000075 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001682852-26-000150 |
| Current Ratio | 2.29x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 8.69x | (Cash + Short-term Investments) / Total Debt | OK | 0001682852-26-000150 |
| Revenue per Diluted Share | $4.25 | Revenue / Diluted Shares | OK | 0001682852-26-000150, 0001682852-25-000075 |